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Available online at www.sciencedirect.comAsthma is the most common chronic respiratory disease and its
prevalence is on the increase. Respiratory viral infections in early
life have been suggested to increase the risk of development of
asthma in later life and virus infection remains the single greatest
precipitant of asthma exacerbations. The development of
effective anti-viral treatments remains a key target for
therapeutic intervention. Here we discuss the role of respiratory
viral infection in asthma exacerbation and highlight current and
potential anti-viral agents and their mechanisms of action.
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Introduction
Asthma is a heterogeneous airway disease characterised by
airway inflammation, airway hyperreactivity, reversible
bronchoconstriction and airway remodelling. Patients
experience shortness of breath, fluctuations in normal
breathing patterns, and also periodic episodes of wheeze
and cough. Asthma is treated with inhaled corticosteroids,
with and without other therapies including short or long
acting bronchodilators. Asthma exacerbations (AEs) are the
major cause of morbidity, mortality and healthcare costs
associated with asthma [1,2], and are generally defined as
worsening of the above symptoms accompanied by a drop
in lung function prompting a GP consultation or visit to the
emergency room. In extreme cases, AE can require oral
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www.sciencedirect.com corticosteroid therapy, supplemental oxygen and may
result in death. Respiratory virus infections account for
at least 80% of exacerbations in adults and children [3–6]
and among respiratory viruses human rhinoviruses (RVs)
are by far the most common viruses associated [3,6,7].
The importance of respiratory viruses as triggers of AE
has therefore made them a target for therapeutic inter-
vention. In this review we discuss the potential of two
therapeutic approaches, one targeting host factors that
may induce natural anti-viral immunity, such as the
addition of an anti-viral cytokine, manipulation of the
host’s immune response such as administration of a
vaccine, and secondly targeting the virus itself; in-
cluding small molecule inhibitors of virus replication,
and virus specific immunotherapy. These approaches
are summarised  in Figure 1. Because of the overwhel-
mingly important role viruses play in AE, we argue that
now is the time to carefully re-consider anti-viral inter-
ventions for AE.
Respiratory viruses are potent exacerbators
of asthma
Respiratory virus infections are triggers of AE. Viruses
such as RVs, respiratory syncytial virus (RSV), seasonal
influenza A viruses, metapneumoviruses, coronaviruses
and bocaviruses may all trigger AE in adults and children.
Atypical bacteria Mycoplasma pneumoniae (M. pneumoniae)
and Chlamydophila pneumoniae (C. pneumoniae) are also
common respiratory pathogens associated with AEs in
both adults and children [8–10]. The major viruses associ-
ated with AEs are RVs, accounting for approximately 60%
of all AE in all ages [6,7]. RVs are members of the
Picornaviridae, and are positive sense ssRNA viruses with
genomes of 7.1–7.5 kb and can be divided into major and
minor groups based on receptor utilisation. Major group
RVs bind ICAM-1 while minor group RVs bind the LDL
receptor. RVs may also be classified based on nucleotide
sequence identity (RV-A, RV-B, RV-C). The RV-C group
[11,12] have unique sequences at the ICAM-1 and LDL
receptor binding sites, suggesting they use a unique,
currently unknown receptor [13]. RVs represent a
diverse group of viruses with 100 serotypes known and
an estimated further 60 or so group C viruses. RV-C may
cause more severe AEs, although how this occurs is
currently unknown [12]. In the northern hemisphere,
RV infection precipitates an increase in emergency room
admissions due to AEs [14], known as the ‘asthma epi-
demic.’ This occurs in the third week of September, after















1. Suppression of virus-augmented Th2 immunity
-Type I IFN therapy
-TLR7/8 agonists
2. Prevention/suppression of 
virus infection or replication 
- Small molecule anti-virals





















Anti-viral approaches may (1) prevent viruses acting in a synergistic or additive manner with allergens, and cause immune deviation to a Th1 rather
than Th2 immune response. Anti-viral approaches may be (2) agents that prevent virus infection or replication at mucosal surfaces and prevent
epithelial damage, inflammation, mucous production, activation of macrophages and attraction of neutrophils into the lung, which promote further
inflammation and damage.children are vectors for RV infection and their crucial role
in AEs [7]. Major and minor group RV mouse models of
RV infection [15,16] and RV induced exacerbations of
airway allergen challenge [15,17] have also recently
been developed. These animal studies mirror the human
data gathered to date and support the idea that RV
infection augments airways inflammation caused by aller-
gen sensitisation and challenge, providing further evi-
dence that respiratory viruses such as RV exacerbate
asthma.
Targeting host factors
Type I IFN therapy
Recent studies have reported that impaired innate
immunity to virus infections is important in the patho-
genesis of AEs. Reduced capacity to induce type I
interferons (IFNs) IFN-a, IFN-b or type III IFNs,
the IFN-ls upon challenge with respiratory viruses or
the dsRNA mimetic polyIC in bronchial epithelial cellsCurrent Opinion in Pharmacology 2013, 13:331–336 (BECs), bronchoalveolar lavage (BAL) macrophages,
dendritic cells (DCs) and peripheral blood mononuclear
cells (PBMCs) from persons with asthma have recently
been described [18,19,20,21,22,23,24,25,26].
Importantly, deficient IFN-l was also strongly related
to virus load, and AE pathogenesis and severity in vivo
[22]. The mechanism responsible for impaired IFN-a,
IFN-b and IFN-l remains poorly understood. However,
the above studies advocate a role for IFN therapy in AE.
Recently, a phase II placebo controlled trial of inhaled
IFN-b in poorly controlled adult atopic asthmatics was
performed [27]. Inhaled IFN-b, started at the reporting
of a clinical cold, showed promise, reducing rates of AE in
this group and increasing lung function. Virus load was
studied in only a few patients, and showed trends for
lower virus loads in treated patients. Therefore, inhaled
IFN-b improves AE rates and associated symptoms, most
likely due to a direct anti-viral activity. It is also possible
that IFN-b could modulate additional processes, such aswww.sciencedirect.com
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have shown that IFN-b and type III IFN-l have potent
Th2 antagonistic activity [28,29], suggesting that
inhaled IFN-b may deliver a benefit on two levels in
atopic asthma, firstly reducing virus replication and
hence virus driven inflammation, and secondly dampen-
ing the Th2 responses to allergens. Further studies with
inhaled IFN-b in AE are eagerly anticipated.
Macrolide antibiotics
Macrolides have been shown to have anti-inflammatory
[30], bactericidal [31] and recently anti-viral activity [32].
The keto-macrolide telithromycin had previously shown
efficacy in AE in adult asthmatics in a phase IV clinical
trial [10]. The mechanism responsible for this beneficial
effect is unknown, and telithromycin could have been
merely acting as an anti-inflammatory agent. In cell based
assays, azithromycin, but not the closely related erythro-
mycin or telithromycin, was shown to have anti-viral
activity to RV by inducing IFN and interferon stimulated
genes (ISGs) [32]. This was a previously unknown
property of azithromycin, and has since promoted the
further investigation of azithromycin in phase IV clinical
trials in AE which are currently ongoing.
Toll like receptor (TLR) 7/8 agonists
TLR7/8 recognise synthetic and virus encoded ssRNA
and small analogues of nucleic acids including imiqui-
mod, R848 and their derivatives. TLR7/8 are expressed
on cells of myeloid or lymphoid origin including macro-
phages and DCs. While viruses certainly induce inflam-
mation via recognition of ssRNA, the addition of TLR7/8
agonists in mouse models of allergen sensitisation and
challenge [33,34] show a suppression of allergic airway
inflammation. Why TLR7/8 agonists are protective in
these models is not completely understood; however, it
is generally accepted that TLR7/8 ligation may be useful
in treating allergic diseases such as asthma. For example,
recent studies of allergic airways inflammation following
sensitisation and challenge to ovalbumin showed that the
TLR7 agonist R848 was protective [33,34], reducing
eosinophilic inflammation, lung function impairment
and ovalbumin-specific Th2 T cell responses. Impor-
tantly, the effects of R848 were not observed in TLR7
deficient mice, showing that R848 acts as a TLR7 agonist
and the protective effect is via TLR7 signalling [33].
Vaccines
The number of viruses implicated in the aetiology of
asthma and their associated antigenic diversity has thus
far limited development of effective vaccines.
There are a number of potential RSV vaccine candidates
although none are currently licensed for use [35–38]. The
creation of an effective RSV vaccine was significantly
affected following the use of formalin inactivated RSV
(FI-RSV) vaccine in the 1960s which led to increasedwww.sciencedirect.com morbidity and enhanced respiratory disease following
infection with live virus and the subsequent deaths of
2 children [39,40]. This phenomenon was felt to be as a
result of induction of Th2 immune responses by the
vaccine [41,42].
A new development in the creation of vaccines has been
the use of TLR ligands as adjuvant agents. One recent
study using monophosphoryl lipid A (MPLA), a deriva-
tive of bacterial LPS, incorporated with RSV virosomes
demonstrated an enhanced Th1 response with increased
production of IFN-g and decreased IL-5 in animals
immunised with vaccine and then challenged with virus
[36]. The MPLA adjuvanted vaccine conferred similar
protection from live RSV virus as FI-RSV vaccine but
with no evidence of enhanced respiratory disease. In
addition the use of MPLA led to enhanced immunogeni-
city of the RSV vaccine with production of higher affinity
antibodies.
The only vaccines commercially available and recom-
mended for use are against influenza where the annual
vaccine has been shown to play a key role in the preven-
tion of virus infection and its associated morbidity [43].
This preventive approach may well have advantages over
treatment of acute viral infections where current treat-
ment options are limited.
As RV infections are implicated in the vast majority of
virus induced AEs they are perhaps the most attractive
target for a respiratory vaccine. However, there are >100
serotypes of RV and unlike influenza there is limited
epidemiological information regarding the most import-
ant circulating serotypes [11]. Humans are infected with
RV in early life and recurrently through life and most
adults have antibodies to multiple RV strains, complicat-
ing human study of antibody responses. Improved diag-
nostic and molecular techniques have recently allowed
the identification of the RV-C group further highlighting
the difficulty in selecting specific serotypes for vaccine
generation [11].
A major hurdle to the understanding of antibody pro-
duction following virus infection has been a scarcity of
animal models that have allowed us to study both
asthma exacerbations and the subsequent effects of
immunisation in greater detail [15]. A recent paper
describing a novel mouse model of RV infection and
immunisation has allowed study of RV mediated induc-
tion of antibody responses [44]. This paper demon-
strated the generation of strong cross-serotype IgG
responses to the RV capsid protein VP1 and that
multiple infections were necessary to induce neutralis-
ing antibodies [44]. Another group have also recently
shown that use of a recombinant VP1 protein was able to
generate neutralising antibodies displaying cross-reac-
tivity to distantly related RV strains [45]. These studiesCurrent Opinion in Pharmacology 2013, 13:331–336
334 Respiratorysuggest that efforts to develop RV vaccines may be
worth re-visiting.
Targeting the virus
Small molecule inhibitors of virus infection and
replication
Using small molecule inhibitors of RV infection, replica-
tion or release was a popular theme in the 1980s and 1990s
for the treatment of the common cold. Despite approaches
showing some promise in common cold studies, the use of
these anti-virals has yet to be examined in virus induced
AE. Small molecule anti-virals offer the advantages of
being cost effective (small molecule production and vali-
dation), and their selectivity and safety is relatively
straightforward to establish. They have disadvantages in
that they may be limited to specific virus types, may select
for escape mutants over time and may suffer from toxicity
or have side effects with continual use.
The anti-RV agent Pleconaril was used in randomised,
placebo-controlled, phase II clinical trials as a treatment
of the common cold [46]. Pleconaril prevents uncoating of
most serotypes of RVs. Pleconaril was tested as a thera-
peutic agent, with infected individuals beginning therapy
1–1.5 days after experiencing clinical colds. Pleconaril
showed significant improvement in mean symptoms
scores and decreases in mean duration of illness. Despite
promising initial results, Pleconaril was abandoned as a
treatment due to side effects.
The RV 3C protease inhibitor Ruprintrivir was tested in a
double blind, placebo-controlled phase II trial of exper-
imental RV39 challenge [47]. Ruprintrivir was designed
to bind irreversibly to the RV 3C active site. As a pro-
phylaxis, Ruprintrivir reduced mean total symptom score,
viral titre and nasal secretions but not the incidence or
frequency of clinical colds. As a therapeutic treatment,
Ruprintrivir also reduced symptom scores, nasal
secretions and viral titre.
The soluble ICAM derivative Tremacamra was tested in
randomised double-blind placebo-controlled studies both
as a therapeutic and prophylactic intervention to RV39
challenge [48]. Tremacamra showed promise as a therapy,
reducing the frequency of colds, total symptom score,
nasal mucus weight, and virus induced inflammation.
Quercetin is a polyphenol which has a range of properties
some of which are anti-viral. Quercetin is thought to
inhibit phospho-inositol-3-kinase inhibition and inhi-
bition of viral endocytosis, RV and poliovirus protease
activity, and RNA polymerase activity of some RNA
viruses. In a mouse model of RV infection, Quercetin
if given during infection reduced virus titre and improved
lung function. However, if given daily for 10 days finish-
ing 40 hours before RV infection, Quercetin had little
effect on virus replication and lung function [49].Current Opinion in Pharmacology 2013, 13:331–336 Development of all these drugs was abandoned for var-
ious reasons. However, considering the role of viruses in
AE, and the available human and mouse models of virus
induced AE, there has never been a better time to trial
small molecule anti-virals as therapies for AE. The future
is likely to witness further studies of anti-virals as a
potential treatment for virus-induced AE.
Virus specific antibodies
The recombinant monoclonal antibody (MAb) Palivizu-
mab has been licenced for use in human RSV immuno-
prophylaxis since 1998 [50]. It acts against an epitope in
the A region of the RSV fusion protein and has been
shown to reduce the rate of hospitalisations in high risk-
infants when used prophylactically [50]. There is a scar-
city of evidence regarding the role of Palivizumab in the
treatment of acute RSV disease with evidence predomi-
nantly limited to case reports and small retrospective
studies. A single dose of 15 mg/kg in children intubated
with respiratory failure due to RSV was shown to reduce
RSV concentration in tracheal aspirates [50] and Palivi-
zumab has been shown to be well tolerated in adult stem
cell transplant recipients [51]. However, there is a need
for further large scale studies to assess the role of Pali-
vizumab as therapy in RSV infection.
Motavizumab (MEDI-524, MedImmune) is a second
generation MAb developed from Palivizumab by affinity
maturation [52]. In comparison to Palivizumab, it has
been shown to bind to RSV F protein 70-fold better and
have an approximately 20-fold improvement in neutral-
isation of RSV in vitro [52] as well as being able to reduce
pulmonary RSV titres up to 100-fold lower than equiv-
alent doses of Palivizumab [52]. Motavizumab is able to
inhibit viral replication in the upper respiratory tract
making it a potentially attractive therapy for treatment
of RSV infection [52]. A study comparing Motavizumab
with Palivizumab for RSV prophylaxis showed that
Motavizumab treatment resulted in 50% fewer RSV
related lower respiratory tract infections needing medical
attention [53]. However, this study also documented an
increase in cutaneous hypersensitivity reactions and
Motavizumab is not currently licenced for use in humans.
There has been a growing body of work directed towards
the generation of MAbs against influenza. Two recently
described MAbs, Fi6v3 and PN-SIA28, have been shown
to be broadly neutralising against both group 1 and 2
influenza A subtypes [54,55]. Fi6v3 antibody was
generated from single cell culture of plasma cells from
individuals following natural influenza A infection or
vaccination and passive transfer of this MAb was protec-
tive in both mice and ferrets against H1, H3 and H5
subtypes [54]. PN-SIA28 was identified from a single
healthy donor who had a negative history for influenza in
the preceding decade and it too demonstrated neutralis-
ing activity against group 1 and 2 subtypes [55]. Bothwww.sciencedirect.com
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have identified new mechanisms underlying virus–host
interaction and new areas of interest in development of
anti-viral therapies [54,55]. There are currently no
MAbs available for use against RV.
Concluding remarks
Current treatment options for AE are limited and have
developed little in recent years. Furthermore, these
treatments do not address the cause of the exacer-
bations, nor specific mechanisms involved in their
pathogenesis.  New clinical studies are needed to further
our understanding of the mechanisms of virus induced
AE so that targets for development of novel approaches
to prevention and therapy can be identified. Anti-viral
therapies may be a source of these new therapies; this
review has highlighted potential therapies that target
the virus or boost host response to the virus. The latter
approach is based on recent studies that show an impair-
ment in the ability of the asthmatic host to raise an
effective anti-viral immune response, and there are
several potential ways to restore this. Alternatively,
the virus itself may be targeted, using specific anti-virals
or immunotherapy. We believe the future will likely
see greatly increased study of anti-viral therapies in
one form or another for treatment/prevention of virus
induced AE.
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